JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Cameron D. Wright
John C. Wain
Ashby C. Moncure
Hermes C. Grillo
Douglas J. Mathisen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, C. D.
Right arrow Articles by Mathisen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, C. D.
Right arrow Articles by Mathisen, D. J.

J Thorac Cardiovasc Surg 1997;114:811-816
© 1997 Mosby, Inc.

GENERAL THORACIC SURGERY

INDUCTION THERAPY FOR ESOPHAGEAL CANCER WITH PACLITAXEL AND HYPERFRACTIONATED RADIOTHERAPY: A PHASE I AND II STUDY

Cameron D. Wright , MD, John C. Wain , MD, Thomas J. Lynch , MD, Noah C. Choi , MD, Michael L. Grossbard , MD, Robert W. Carey , MD, Ashby C. Moncure , MD, Hermes C. Grillo , MD, Douglas J. Mathisen , MD, From the Sections of Thoracic Surgery, Medical Oncology, and Radiation Oncology, Massachusetts General Hospital, Boston, Mass.

Received for publication May 12, 1997 revisions requested June 26, 1997; revisions received July 21, 1997 accepted for publication July 21, 1997. Address for reprints: Cameron D. Wright, MD, Thoracic Surgery, Blake 1570, Massachusetts General Hospital, Boston, MA 02114.

Abstract

Objective: Induction chemoradiotherapy followed by surgery may improve survival rates among patients with esophageal carcinoma. We designed a novel intense induction regimen with paclitaxel and high-dose hyperfractionated radiotherapy to maximize complete response rates. Methods: Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58.5 Gy to the tumor). The mean age was 62 years, and 32 patients(80%) had adenocarcinoma. Twenty-eight of 40 (70%) patients had locally advanced tumors (T3, or stage IIB or greater). Results: The average hospitalization for induction treatment was 17 days. Toxicity was substantial, with esophagitis necessitating nutritional support the most common complication. The maximum tolerated dose of paclitaxel was 100 mg/m2. Two patients died during induction treatment. Thirty-six patients (90%) underwent resection. The median length of stay was 10 days, and two patients died after the operation. Fourteen of 36 patients (39%) had a pathologic complete response. Patients who received all prescribed chemotherapy had a higher pathologic complete response rate (50%) than did patients who required dose reduction (17%; p = 0.076). The 2-year survival rate was 61% (95% CI 35% to 86%) with a median follow-up of 11.9 months. Conclusions: Paclitaxel at a dose of 100 mg/m2 appears to have acceptable toxicity. The high pathologic complete response rate in this regimen is encouraging, but it is associated with substantial toxicity. The toxicity of this regimen is not acceptable and will require substantial reduction in the radiation component. Survival data are too short-term to confirm enhanced survival.




This article has been cited by other articles:


Home page
 Am Soc Clin Oncol Ed BookHome page
D. H. Ilson
Combined Modality Therapy for Gastric, Esophageal, and Gastroesophageal Junction Cancers
ASCO Educational Book, January 1, 2008; 2008(1): 177 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Ilson, R. Wadleigh, L. Leichman, and D. Kelsen
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
Ann. Onc., May 1, 2007; 18(5): 898 - 902.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. de Manzoni, C. Pedrazzani, E. Laterza, F. Pasini, A. Grandinetti, M. Bernini, A. Ruzzenente, G. Zerman, A. Tomezzoli, and C. Cordiano
Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results
Ann. Thorac. Surg., October 1, 2005; 80(4): 1176 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-L. Lee, S. I. Park, S.-B. Kim, H.-Y. Jung, G. H. Lee, J.-H. Kim, H.-Y. Song, K.-J. Cho, W.-K. Kim, J.-S. Lee, et al.
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
Ann. Onc., June 1, 2004; 15(6): 947 - 954.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Goldberg, J. Farma, C. Lampert, P. Colarusso, L. Coia, H. Frucht, E. Goosenberg, M. Beard, and L. M. Weiner
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: A phase I report
J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1168 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Ilson, M. Bains, D. P. Kelsen, E. O'Reilly, M. Karpeh, D. Coit, V. Rusch, M. Gonen, K. Wilson, and B. D. Minsky
Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer
J. Clin. Oncol., August 1, 2003; 21(15): 2926 - 2932.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. S. Waters, D. Tait, D. Cunningham, A. R. Padhani, M. E. Hill, S. Falk, F. Lofts, A. Norman, J. Oates, and A. Hill
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus
Ann. Onc., November 1, 2002; 13(11): 1763 - 1770.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. S. Bains, A. Stojadinovic, B. Minsky, V. Rusch, A. Turnbull, R. Korst, R. Ginsberg, D. P. Kelsen, and D. H. Ilson
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results
J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 270 - 277.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. S. Allen and E. C. Sheffer
Case 22-2000- A 74-Year-Old Man with Unrelenting Dysphagia
N. Engl. J. Med., July 20, 2000; 343(3): 199 - 205.
[Full Text] [PDF]

Home page
 ChestHome page
C. D. Wright
Multimodality Therapy of Esophageal Cancer*
Chest, December 1, 1999; 116 (2009): 461S - 462S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. Lerut, W. Coosemans, P. De Leyn, D. Van Raemdonck, G. Deneffe, and G. Decker
Treatment of Esophageal Carcinoma*
Chest, December 1, 1999; 116 (2009): 463S - 465S.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. D. Wright, U. Fink, H. J. Stein, J. Fleeth, F. Begemann, A. Y. Chang, D. Kelsen, T. Pajak, and R. Ginsberg
Treatment of Esophageal Cancer
N. Engl. J. Med., May 27, 1999; 340(21): 1685 - 1687.
[Full Text]

Home page
 The OncologistHome page
C. E. Reed
Surgical Management of Esophageal Carcinoma
Oncologist, April 1, 1999; 4(2): 95 - 105.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The American Association for Thoracic Surgery.